Grants for For profit organizations other than small businesses - Science and Technology

Village Capital, in collaboration with the Deloitte Health Equity Institute (DHEI) and with support from Impact Ventures by Johnson & Johnson Foundation, is launching a call for applications for the “LIFT: Accelerating Equitable Health Innovation” accelerator. Donor Name: Village Capital State: All States County: All Counties Type of Grant: Program Deadline: 05/06/2024 Size of the Grant: $1000 to $10,000 Grant Duration: Grant Duration Not Mentioned Details: LIFT: Accelerating Equitable Health Innovation will work with ten startups advancing health equity across the US. This accelerator program will focus on supporting non-medical solutions that address disparities in the social drivers of health for historically marginalized communities. From June to September 2024, the selected startups are expected to work closely with industry experts, investors, and ecosystem partners and will participate in a one-week intensive workshop, followed by monthly check-ins, and one in-person Summit. A founder/C-suite member of each selected startup will travel with all expenses included to the Summit. This hybrid program will support ten startups. Village Capital is seeking startups across the US focused on addressing critical non-medical drivers of health and with the mission to improve health outcomes for historically marginalized communities including, but not limited to, Black, Hispanic, APPI (Asian, Pacific Islander), and AIAN (American Indian, Alaska Native) individuals, low-income, LGBTQ+, disabled, or rural communities. What they are looking for? Focus on reducing health bias and equity gaps Solutions supporting historically marginalized communities facing health challenges and inequities. Focus on building trust in underserved communities Solutions engaging and strengthening communities. Cultural and behavioral sensitivity Solutions that use a creative, cultural, and behavioral lens. Lived experience Founders who are building solutions for challenges they have experienced or communities from which they come. Benefits startups will receive: Mentorship Mentorship from potential strategic partners, customers, founders, prominent US investors, and business leaders. Connections & Exposure Access to a diverse and inclusive network of mentors and founders within healthcare and healthtech. Exposure on Village Capital’s program website and other communications collateral. Financial Analysis & Support 1:1 coaching with an investment analyst focused on building a financial model, identifying unit economics, and on using financial metrics to drive both their business and investor diligence. Continued Learning Participate in mock board meetings with representatives from enterprise healthcare organizations, corporations, and investors that can help their organization scale. Events Interactive virtual workshops tailored to help your company identify early milestones and prepare them for your next round of capital (if relevant), and one in-person program summit. Funding All startups will receive a USD 10K non-dilutive grant. Eligibility Criteria  Eligible startups must have: Legal incorporation as a for-profit entity. Headquartered and with operations in the United States. Market-based solution that tackles the challenges above for communities in the US. Have a minimum viable product (MVP), and raised less than USD 1.5M in equity. Have at least one full-time founder based in the US. Have meaningful customer or business validation (not limited to revenue, it can also be successful pilot studies, number of users, and/or strategic partnerships). For more information, visit Village Capital.

The Alameda Countywide Clean Water Program is inviting grant applications for community-based projects that prevent stormwater pollution, enhance the health of local watersheds, creeks and the San Francisco Bay, and have a public outreach element. Donor Name: Alameda County Resource Conservation District State: California County: Alameda County (CA) Type of Grant: Grant Deadline: 05/10/2024 Size of the Grant: $1000 to $10,000 Grant Duration: Grant Duration Not Mentioned Details: Types of projects will be funded Community Stewardship Grants provide funding for creative and innovative projects that prevent stormwater pollution and/or educate about stormwater pollution prevention. Projects must contain a community/public outreach element. Projects must be implemented in Alameda County. Funding Information Individual grant amounts range from $500 to $6,000, with $30,000 of total grant funding available. Eligible projects include (but are not limited to): Litter reduction projects Outreach and education projects addressing litter reduction/prevention, household hazardous waste disposal, Integrated Pest Management, etc. Development and distribution of outreach materials, e.g. videos, newsletters, brochures, events, etc. Public art projects Creekside restoration/re-vegetation projects, creek cleanup and enhacement projects Stormwater detention projects such as rain gardens, cisterns and bioretention areas Coastal and/or creek cleanups and other creek enhancement projects Wildlife habitat enhancement projects Eligibility Criteria Teachers and student groups, service clubs, community groups, environmental groups, youth organizations, homeowner associations, and non-profit organizations are eligible. For-profit groups and public agencies including Clean Water Program Member agencies are not eligible. If the applicant is not a formal nonprofit (501(c)(3)), they must obtain a fiscal sponsor, which is an organization legally qualified to receive checks for grant funds and write checks for the project. Grant funds cannot be distributed to personal checking accounts. For more information, visit Alameda County Resource Conservation District.

The Women’s Foundation of Arkansas (WFA) is seeking candidates for the fifth Women’s Economic Mobility Hub cohort. Donor Name: Women’s Foundation of Arkansas State: Arkansas County: All Counties Type of Grant: Program Deadline: 05/20/2024 Size of the Grant: $1000 to $10,000 Grant Duration: Grant Duration Not Mentioned Details: The 2024 Women’s Economic Mobility HUB Program supports Black women-owned businesses by providing technical assistance along with additional resources, including $5,000 in unrestricted grant funds to help scale their businesses. An ideal WEM Hub participant will be able to commit to a six-month program in which Black women entrepreneurs can access tailored support services through a combination of online trainings and in-person meetings, including: Expert advice from leading industry professionals surrounding topics such as accounting and financial management, business development, legal services, and more; Ongoing mentorship support and counsel; Peer to peer learning sessions; Communications, public relations, and marketing training; Leadership skill development; and Opportunity to establish a relationship with participating financial institutions. Eligibility Determination Applicants will be selected based on the following criteria: Must be able to participate in (via teleconference and/or in person) six, two hour monthly WEM Hub sessions, which will include technical assistance and/or networking events. Please note that the required WEM Hub Orientation and Closing Sessions will be held in person in Central Arkansas on June 27 and December (TBD), respectively.  Exact location to be determined. Must be an existing business in which 75% is owned and operated by one or more Black women who are U.S. citizens. Must be a bona-fide registered business physically located and operating for more than one year within the state of Arkansas. Must be an entity operating as a for-profit corporation, partnership, LLP or LLC, or sole proprietorship. Not-for-profit corporations or similar non-profit entities are not eligible. Must be in good standing with the Arkansas Secretary of State and be current on all county, state, and federal taxes. For more information, visit Women’s Foundation of Arkansas.

Propeller’s Impact Accelerator is a 5-month program that provides mission-driven entrepreneurs with coaching, community building, curriculum, and technical assistance to grow their businesses. Donor Name: Propeller State: Louisiana City: New Orleans Type of Grant: Program Deadline: 05/12/2024 Size of the Grant: Not Available Grant Duration: Less than 1 Year Details: In the Impact Accelerator, Propeller works with entrepreneurs to catalyze transformational growth. Propeller connects entrepreneurs with the contract opportunities, markets, and customers to put their businesses on the fast track for growth. Ventures begin their Impact Accelerator experience by working with experienced, dedicated mentors to set ambitious yet achievable goals for growth and long-term sustainability, tailored to the needs of your business. Each venture receives support from subject matter experts to provide project assistance and access to entrepreneurial curriculum to remove speed bumps to growth. Propeller’s Impact Accelerator is sponsored by the Clif Family Foundation, Capital One, Nasdaq, RosaMary Foundation, WK Kellogg Foundation, Baptist Community Ministries. Focus Areas  Community Economic Development In community economic development, Propeller’s Impact Accelerator supports BIPOC entrepreneurs operating brick and mortar establishments along the Broad Street corridor, in New Orleans East, and in Central City seeking to grow their revenues and staff. Education In education, Propeller’s Impact Accelerator supports entrepreneurs working in the service provision or delivery of early childhood education and care from birth to eight years of age. Food In food, Propeller’s Impact Accelerator supports entrepreneurs who have an existing consumer packaged goods (CPG) brand with an emphasis on sustainable, healthy, and affordable products made with locally-sourced ingredients. Health In health, Propeller’s Impact Accelerator supports entrepreneurs who provide direct health and wellness services, including clinical care, and services that address the social and physical determinants of health in the built environment and community context domains. Propeller prioritizes entrepreneurs who serve a BIPOC client base. Water In water, Propeller’s Impact Accelerator focuses on supporting entrepreneurs working in the fields of green infrastructure, urban stormwater management, native plants cultivation, and coastal restoration. Benefits Impact Accelerator participants have regular Lead Mentor office hours to set goals for growth and sustainability, receive support from Subject Matter Experts, and attend in-person meetups to access entrepreneurial curriculum.  A summary of program benefits include: 16+ hours of Lead Mentor Office Hours 12+ hours of business development curriculum during Meetups 20+ hours to work with Subject Matter Experts on projects related to business growth goals A detailed work plan laying out revenue, capital, and social/environmental impact goals Coaching to embed racial equity, social and environmental impact goals into business operations Introductions to key community stakeholders Free coworking office space at Propeller’s facility Membership in a cohort of 20 like-minded entrepreneurs, as well as a network of over 250 alumni. Eligibility Criteria  Propeller is seeking growth stage entrepreneurs with plans to scale revenues and teams over the next 12 months in Propeller’s five areas of focus: community economic development, education, food, health, and water. Community Economic Development Eligibility Category: Black-owned Brick and Mortar Storefronts For-profit Operating a brick-and-mortar storefront Headquartered on or along North/South Broad Street, Central City, or New Orleans East Majority (50%+) owned by Black entrepreneur(s) Preferred: Storefront business that has existed in the neighborhood for 3+ years with the desire to stay in the neighborhood, create livable wage jobs, and build strong community ties Preferred: Businesses with stated intention of growing revenues and team through commercial and/or government contracts. Education Eligibility Category: Early Childhood Education For-Profit or Non-Profit Supports service provision or delivery of early childhood education and care from birth to eight years of age Plans to increase enrollment, grow staff, and/or expand business location within the next 12 months. Education Eligibility Category: Consumer Packaged Goods Entrepreneurs who have an existing consumer packaged goods (CPG) brand that are one or more of the following: Environmentally sound Locally sourced Healthy Or have other compelling social or environmental impacts Propeller will prioritize companies led by BIPOC entrepreneurs, especially those seeking to increase sales through growth of wholesale outlets. Health  Eligibility Category: Direct provision or delivery of healthcare For-profit or nonprofit with earned revenue Providing direct clinical care or healthcare Preferred: Entrepreneurs serving a BIPOC client base Preferred: Entrepreneurs seeking to make healthcare more accessible to New Orleanians Preferred: Entrepreneurs seeking to grow their staff in the next 12 months Eligibility Category: Provision of services impacting social and physical determinants of health For-profit or nonprofit with earned revenue Providing services impacting social and physical determinants of health Preferred: Entrepreneurs serving a BIPOC client base Preferred: Entrepreneurs seeking to make healthcare more accessible to New Orleanians Preferred: Entrepreneurs seeking to grow their staff in the next 12 months. Water  Eligibility Category: Green Infrastructure and Stormwater Management Currently working urban stormwater management or green infrastructure For-profit or nonprofit with earned revenue Eligibility Category: Coastal Restoration Currently working or seeking to work in coastal restoration For-profit or nonprofit with earned revenue Eligibility Category: Native Plant Cultivation For-profit or nonprofit with earned revenue Priority: increasing supply of native plants to be used in green infrastructure projects. For more information, visit Propeller.

The City of Provo and Utah Valley HOME Consortium announce the availability of $1,759,085.00 in HOME Investment Partnership – American Rescue Plan (HOME-ARP) funding for the acquisition and development of a non-congregate shelter (NCS) that will serve individuals fleeing or attempting to flee domestic violence, dating violence, sexual assault, stalking and human trafficking. Donor Name: City of Provo State: Utah County: Utah County (UT) City: Provo Type of Grant: Grant Deadline: 05/20/2024 Size of the Grant: Not Available Grant Duration: Grant Duration Not Mentioned Details: Eligible Projects  May include but are not limited to the acquisition of land and construction of noncongregate shelter (NCS) or acquisition and/or rehabilitation of existing structures such as motels, hotels, or other facilities to be used for NCS. No funds may be used to fund any costs associated with the operation of a non-congregate shelter. Qualifying Population HOME-ARP NCS units may only be occupied by individuals or families who are fleeing, or attempting to flee, domestic violence, dating violence, sexual assault, stalking, or human trafficking, as defined by the Department of Housing and Urban Development 24 CFR 5.2003. Eligible Applicants  Eligible applicants may be Nonprofit, governmental, and/or quasi-governmental agencies; housing authorities; for profit entities serving the defined Qualifying Population above within the Utah Valley HOME Consortium boundaries (Provo City and Utah County Excluding Eagle Mountain, Alpine and Fairfield). For more information, visit City of Provo.

The Community Reinvestment Fund, a capital grant program, shall be used for community redevelopment, revitalization and investment capital projects which will improve the economic, culture, historical, and recreational health of Delaware communities. Donor Name: Delaware General Assembly State: Delaware County: All Counties Type of Grant: Grant Deadline: 05/15/2024 Size of the Grant: Not Available Grant Duration: Grant Duration Not Mentioned Details: Project Eligibility Eligible project funding requests include preconstruction costs, land acquisition, building construction or other capital costs. Such projects may include, but are not limited to, the following: Preconstruction costs, to include development of plans and specifications for the capital project. The acquisition, construction, reconstruction, rehabilitation, or restoration of buildings. The acquisition or installation of apparatus or equipment permanently attached to the building. The acquisition of land required as sites for such buildings, including land or rights to land needed to provide access to sites, and the grading or other improvements of such sites, land or rights in land. The construction of sidewalks where authorized by law. The construction of any sewers or water mains needed to connect such buildings to any publicly owned sewer system or water system. Eligibility Criteria Eligible entities include county and local governments, community-based nonprofit, and private sector nonprofit organizations. All nonprofit organizations must hold a 501(c)3 designation in order to be considered eligible. Designation must be held at the time of application. State agencies, school districts, charter schools, private schools, institutions of higher education, childcare facilities, churches, fire companies, fiscal agents, and for-profit organizations are not eligible for funds from the Community Reinvestment Fund. For more information, visit Delaware General Assembly.

The Kalamazoo Community Foundation (KZCF) is seeking applications for its Women’s Education Coalition Grant Program. Donor Name: Kalamazoo Community Foundation (KZCF) State: Michigan County: Allegan County (MI), Barry County (MI), Calhoun County (MI), Kalamazoo County (MI), Saint Joseph County (MI), Van Buren County (MI) Type of Grant: Grant Deadline: 05/15/2024 Size of the Grant: Not Available Grant Duration: Grant Duration Not Mentioned Details: Pursue your educational and employment goals with the Women’s Education Coalition Grant Program. Get connected with renewable grant assistance to increase your financial independence and move your career forward. The Women’s Education Coalition is a collaborative of Alpha Kappa Alpha Sorority, Inc.; Delta Sigma Theta Sorority, Inc.; the YWCA of Kalamazoo and the former Kalamazoo Network. The grant can be used to enroll in a professional development opportunity, trade, technology, vocational or certificate program, or an associate’s, bachelor’s or master’s degree program. The grant may be used by part-time or full-time students. Eligibility Criteria Women residing in Kalamazoo, Barry, Calhoun, Allegan, St. Joseph or Van Buren County who have had a significant break in their education or are seeking additional education to improve their career and pay opportunities are eligible. Applicants should be able to demonstrate how post-high school education will assist in reaching goals of increased financial independence. Priority will be given to underemployed working mothers and those enrolling or enrolled in not-for-profit educational institutions. For more information, visit KZCF.

The Neighborhood STAR program awards funding for capital improvement projects in Saint Paul neighborhoods. Donor Name: City of Saint Paul State: Minnesota City: Saint Paul Type of Grant: Grant Deadline: 05/15/2024 Size of the Grant: $10,000 to $100,000 Grant Duration: 2 Years Details: State and local legislation was enacted in 1993 to allocate revenue from the city’s half-cent sales tax to the Neighborhood Sales Tax Revitalization (STAR) Program. Administered by the City’s Department of Planning and Economic Development (PED), Neighborhood STAR provides reimbursement grants of $5,000 or more for capital improvement projects which strengthen the vitality of city’s neighborhoods. Public, private, non-profit, or for-profit entities located in or doing business in Saint Paul may apply for STAR funds. If you choose to apply and require translation services for the application process, please contact STAR staff for assistance. Funding Information Grant requests up to $50,000 do not require matching funds. Anticipated project dates: September 1, 2024 – August 31, 2026. Eligible STAR-Funded Projects and Activities Eligible activities include: Renovation, rehabilitation andor construction of commercial, residential, or industrial property Most fixed interior and exterior improvements to commercial or residential structures including walls, ceilings, floors, lighting, windows, doors, entrances, electrical, plumbing HVAC, energy and security improvements, handicap accessibility, and building code corrections Minor public improvements (major public improvements should be referred to the city’s Capital Improvement Budget (CIB) process) Beautification of public or private open space, including trees and shrubs, rain gardens, benches, play equipment, bicycle parking, and lighting that are site-specific and have a life expectancy of 7+ years. Creative placemaking / placekeeping capital improvement activities, including public art and creative public infrastructure improvements, especially those that contribute to cultural diversity. Non-profit neighborhood organizations providing a funding program to local businesses, homeowners, or condominium/townhome owners for capital improvement activities Eligibility Criteria Public, non-profit, and for-profit entities located in or doing business within the City of Saint Paul City departments and quasi-governmental entities are an eligible applicant when in partnership with a neighborhood and/or community group Churches and religious organizations are eligible to apply when in partnership with a neighborhood and/or community group and only with respect to a project that: (i) is non-sectarian and whose primary effect neither advances nor inhibits religion; (ii) will make capital improvements for functions not associated with church-sponsored or religious type activities; and (iii) is open and available to the public at large on a regular basis Ineligible Applicants Political parties and political action groups Federal, state and county agencies and departments Individual homeowners, condominium, or townhome owners and/or the association representing them For more information, visit City of Saint Paul.

This program provides funding to state entities, higher education institutions, and private businesses in Texas to support new and expanded semiconductor research, design, and manufacturing projects.

Governor Greg Abbott and the Texas Division of Emergency Management (TDEM) have announced the opening of applications for the Department of Energy's (DOE) grant program aimed at enhancing the resilience of electric grids against disruptive events. The program is designed to allocate competitive grants to improve infrastructure and reduce the likelihood and impact of such events on the electrical grid. The grant supports weatherization, fire-resistant technologies, monitoring and control systems, vegetation management, adaptive protections, and advanced modeling technologies. This grant opportunity is now active with a closing deadline of June 28, 2024.

The FY24 PCRP Idea Development Award is intended to support new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP mission. The key components of this award mechanism are: Innovation: Research deemed innovative may represent a new paradigm, challenge current paradigms, look at existing problems from new perspectives, leverage unique study populations, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative. Projects involving multidisciplinary and/or data science approaches are especially encouraged. Impact: Applications are required to address and provide a solution to one or more of the FY24 PCRP Overarching Challenges. The potential impact of the research, both short-term and long-term, in addressing the FY24 PCRP Overarching Challenge(s) should be clearly described. High-impact research will, if successful, significantly advance prostate cancer research and/or patient care. Preliminary Data: Due to this awards emphasis on innovation, the presentation of preliminary data relevant to prostate cancer and the proposed project is encouraged, but not required. Any unpublished, preliminary data provided should originate from the laboratory of the Principal Investigator (PI) or a member(s) of the research team. Regardless of whether preliminary data are included, applications should be based on a sound scientific rationale that is established through logical reasoning and/or critical review and analysis of the literature.New Investigator category: The FY24 PCRP Idea Development Award mechanism encourages research ideas from investigators in the early stages of their careers. The New Investigator category of this award mechanism is designed to allow applicant organizations to name PIs who are early in their faculty appointments or in the process of developing independent research careers. Applications submitted to the New Investigator category will be assessed using different review criteria for personnel (refer to Section II.E.1.a., Peer Review) and are required to include a collaborator (or collaborators) who has (have) experience in prostate cancer research, as demonstrated by a record of funding and publications. The application must describe the potential of the collaboration(s) to be successful and how the collaboration(s) will augment the PIs expertise to better address the research question. In addition, applicants are strongly encouraged to provide a letter of collaboration from the collaborator(s) describing the collaborator(s) involvement in the proposed work. All applicants for the New Investigator category must meet specific eligibility criteria described in Section II.C, Eligibility Information.Multidisciplinary projects are encouraged, and multi-institutional projects are allowed. Each proposed study must include a clearly stated plan for interactions among all team members and organizations involved. The plan must include communication, coordination of research progress and results, and data transfer. Additionally, multi-institutional applications must provide an intellectual property plan to resolve potential intellectual and material property issues and to remove institutional barriers that might interfere with achieving high levels of cooperation to ensure the successful completion of this award.Investigators are strongly encouraged to incorporate the following components into their study design, where appropriate, in order to maximize the potential impact of the proposed research project: authentication of proposed cell lines; statistical rigor of preclinical animal experiments; and incorporation of experiments to assess clinical relevance and translatability of findings. Studies utilizing data that are derived from large patient studies that include long-term health records, biospecimen repositories, and pre-existing research and apply state-of-the-art genomic and/or proteomic analysis, bioinformatics, and/or mathematical models to such data are also encouraged. Investigators are highly encouraged to provide a letter of support indicating access to and the availability of any resources required to support the study.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 https://www.nature.com/nature/ journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP Idea Development Award should not exceed $1.2M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $53.76M to fund approximately 28 Idea Development Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The DoD Peer Reviewed Cancer, Impact Award is a grant aimed at funding advanced research projects that can quickly translate promising findings into clinical applications, with the goal of making a significant, near-term impact on critical cancer issues and improving patient outcomes.

The "DoD Peer Reviewed Cancer, Idea Award" is a grant aimed at supporting innovative and high-risk basic cancer research that introduces new concepts or challenges existing paradigms, with the goal of advancing knowledge in cancer research and treatment for the benefit of Service Members, Veterans, and the American public.

The FY24 PCRP Data Science Award mechanism supports research where quantitative and analytical approaches, processes, and/or systems are developed and/or used to obtain knowledge and insight from large and/or complex sets of prostate cancer data. If successful, the studies will enable progress toward addressing one or more of the FY24 PCRP Overarching Challenges. It is expected that any resources, tools, or computational processes generated by this award will be openly shared with the prostate cancer research and patient community. This mechanism is intended to fund research built upon the logic, concepts, and methods of one or more of the following research areas as they pertain to prostate cancer: Computational biology Bioinformatics Artificial intelligence and machine learning Epidemiology Analysis of omics data Medical imaging Digital pathology Analysis of other clinically annotated datasetsApplications may combine diverse data types for integrative analysis to increase knowledge about prostate cancer with respect to the FY24 PCRP Overarching Challenges. Applications that propose to develop resources or tools that allow research, clinical care, and patient community access to standardized and harmonized datasets for real-time clinical care applications are of particular interest; however, this award must not be used to support the development of new datasets. Studies utilizing data derived from large patient studies that include long-term health records or repositories with well-annotated and high-quality biospecimens are encouraged.Key Features: Research Approach: Applications may propose development of a new data-science-driven tool or apply an existing tool or method to gather and analyze information from large datasets with the intent of advancing prostate cancer research and patient care relative to the FY24 PCRP Overarching Challenges. Inclusion of preliminary data to support the scientific rationale and feasibility of research approaches is strongly encouraged, but not required. Any preliminary data provided should be from the laboratory of the Principal Investigator(s) (PI[s]) or member(s) of the collaborating team. Applicants are encouraged to include plans for rigorous validation, benchmarking, comparisons, and/or evaluations to assess the quality or utility of the tools and/or approaches that will be used or developed under this award. Any datasets used in the study design must be from established, retrospective databases and be sufficient in size to provide appropriate analytical and statistical power. Prospective recruitment of human subjects and/or clinical trials is not allowed under this funding opportunity. Applicants are expected to provide documentation demonstrating access to the appropriate datasets and/or patient samples in numbers sufficient to achieve robust results. Impact: Applications are required to clearly communicate how the proposed quantitative and/or analytical approaches, processes, and/or systems will address and provide a solution to one or more of the FY24 PCRP Overarching Challenges. The potential impact of the research, both short- and long-term, should be clearly described, including how the anticipated outcomes or products are distinct from existing research efforts in this area and/or how they will significantly outperform current approaches in this area. High-impact research will, if successful, significantly advance prostate cancer research and/or patient care. Data and Resource Sharing Plan: It is expected that any resources, tools, and computational processes that are developed under this award will be openly shared with the prostate cancer research and patient community. Plans must be provided for how additional data generated by future studies will be incorporated to further inform and refine the data science tools, processes, and/or methods generated and/or used in this study. Refer to the CDMRPs Policy on Data Resource Sharing located on the Electronic Biomedical Research Application Portal (eBRAP) Funding Opportunities Forms web page https://ebrap.org/eBRAP/public/Program.htm for more information about the CDMRPs expectations for making data and research resources publicly available.Partnering PI Option: The FY24 PCRP Data Science Award encourages applications that include meaningful and productive collaborations between investigators. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application; collaborations between data scientists and clinicians are highly encouraged. The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project, including the Project Narrative, Statement of Work (SOW) and other required components. If recommended for funding, each PI will be named on separate awards to the recipient organization. Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI, refer to Section II.D.2, Content and Form of the Application Submission.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (http://www.nature.com/ nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP Data Science Award should not exceed $1.0M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $11.2M to fund approximately seven Data Science Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The FY24 PCRP Physician Research Award supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. The mentored physician is considered the Principal Investigator (PI) of the application. This award emphasizes equally the quality of the proposed research project and the career development of the PI, which should prepare physicians for careers in basic, population science, translational, or clinical prostate cancer research. All applications for the FY24 PCRP Physician Research Award are to be written by the PI, with appropriate direction from the mentor(s).Key elements of this award mechanism are as follows: Principal Investigator: Physicians with clinical duties and/or responsibilities who, at the application submission deadline, are either in the last year of an accredited graduate medical education program as a resident or fellow or within 5 years of having initiated a faculty appointment (including Instructor positions) are eligible to apply. The PI must demonstrate a commitment to a career as a physician-scientist and investigator at the forefront of prostate cancer research and clinical practice; however, the PI is not required to have previous prostate cancer research experience. The award is intended to provide protection of the PIs time for prostate cancer research. Applications are strongly encouraged to demonstrate protection of at least 20% of the PIs time for prostate cancer research, which is not required to be exclusive to this award but can include effort dedicated to other prostate cancer research projects. Mentor(s): This award requires the involvement of at least one designated mentor with an established research program in prostate cancer, as evidenced by recent publications, active funding, and successful mentorship. In addition, the mentor(s) must demonstrate a commitment to advancing the PIs career in prostate cancer research. Research Approach: Proposed research ideas are required to address one or more of the FY24 PCRP Overarching Challenges. The scientific rationale and experimental methodology should demonstrate in-depth analysis of the research problem presented. The feasibility of the research design and methods should be well defined, and a clear plan should be articulated as to how the proposed goals of the project can be achieved. The inclusion of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required. Any preliminary data provided should be from the PI, mentor(s), or member(s) of the collaborating team. Additionally, required resources should be identified and supported through documentation. Research involving human subjects is permitted under this funding opportunity but is restricted to studies without clinical trials. Correlative studies associated with an existing clinical trial are particularly encouraged, provided they are determined to be no greater than minimal risk by the Institutional Review Board (IRB) of record and the USAMRDC Office of Human and Animal Research Oversight (OHARO), Office of Human Research Oversight. Researcher Development Plan: An individualized researcher development plan is required and should be prepared with appropriate guidance from the mentor(s). The researcher development plan should include a clearly articulated strategy for acquiring the necessary skills, competence, and expertise that will enable the PI to successfully complete the proposed research project and foster the PIs development as an independent prostate cancer physician-scientist. An environment appropriate to the proposed mentoring and research project must be clearly described, although any deficiencies of resources and/or mentorship at the PIs institution can be mitigated through collaboration(s) with other institutions. If the PI will be utilizing resources at another institution to successfully complete the proposed project, then the PI is strongly encouraged to designate a co-mentor at the collaborating institution. Impact: The proposed research must address and provide a solution to one or more of the FY24 PCRP Overarching Challenges and ultimately should have the potential to make a significant impact on the programs mission of eliminating death and suffering from prostate cancer and enhancing the well-being of Service Members and their Families, Veterans, and all the patients and caregivers who are experiencing the impact of the disease.Investigators are strongly encouraged to incorporate the following components into their study design, where appropriate, in order to maximize the potential impact of the proposed research project: authentication of proposed cell lines; statistical rigor of preclinical animal experiments; and incorporation of experiments to assess clinical relevance and translatability of findings. Studies utilizing data that are derived from large patient studies that include long-term health records, biospecimen repositories, and pre-existing research and apply state-of-the-art genomic and/or proteomic analysis, bioinformatics, and/or mathematical models to such data are also encouraged. Investigators are highly encouraged to provide a letter of support indicating access to and the availability of any resources required to support the study.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/ journal/v490/n7419/full/nature11556.html. While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP PRA Award should not exceed $750,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $4.80M to fund approximately four PCRP Physician Research Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The FY24 PCRP Exploration Hypothesis Development Award supports the exploration of highly innovative, untested, potentially high-gain concepts, theories, paradigms, and/or methods that address an important problem relevant to one or more of the FY24 PCRP Overarching Challenges. This award is designed to provide investigators the opportunity to pursue serendipitous observations that may reveal entirely new avenues for investigation. Results of studies conducted through this award may provide the scientific premise upon which a new hypothesis can be based or initial proof of principle of an innovative hypothesis, laying the groundwork for future avenues of scientific investigation. Presentation of preliminary data is inconsistent with the intent of this award mechanism and is therefore strongly discouraged. However, logical reasoning and a sound scientific rationale for the proposed work must be described. Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborator(s), and their organization(s). Refer to Section II.D.2.b.i, Full Application Submission Type, for more information. New for FY24: Clinical research is allowed. For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes: (1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies. (2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. (3) Outcomes research and health services research that do not fit under the definition of clinical trial. Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule. Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials. A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities. Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies. Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/ journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. The funding instrument for awards made under the program announcement will be grants (31 USC 6304). The anticipated direct costs budgeted for the entire period of performance for an FY24 Exploration Hypothesis Development Award should not exceed $150,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. Awards supported with FY24 funds will be made no later than September 30, 2025. The CDMRP expects to allot approximately $3.60M to fund approximately 15 Exploration Hypothesis Development Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030. Research Involving Animals: All research funded by the FY24 PCRP Exploration-Hypothesis Development Award involving new and ongoing research with animals must be reviewed and approved by the USAMRDC Office of Human and Animal Research Oversight (OHARO; previously the Human Research Protection Office), Animal Care and Use Review Office (ACURO), in addition to the local Institutional Animal Care and Use Committee (IACUC) of record. IACUC approval at the time of submission is not required. Allow at least 3 to 4 months for ACURO regulatory review and approval processes for animal studies. Refer to the General Application Instructions for additional information.

The ITP ASH 2024 grant initiative, offered by SANOFI, is designed to identify and fund projects that aim to close significant healthcare gaps related to the treatment and management of Immune Thrombocytopenia (ITP). ITP is a rare blood disorder characterized by a significantly reduced platelet count, leading to a heightened risk of bleeding and serious health complications such as thrombosis and hematologic malignancy. The chronic nature of ITP often results in a diminished quality of life for patients, manifesting in anxiety, fatigue, and depression due to ongoing concerns about bleeding risks and ineffective current therapies. SANOFI is particularly interested in supporting educational and therapeutic strategies that promise to enhance the clinical handling of ITP, focusing on innovative treatment methodologies and educational activities that can lead to improved patient outcomes. Proposals are invited for projects including, but not limited to, live symposiums at medical conferences, enduring materials for broader educational reach, and both accredited and non-accredited Independent Medical Education (IME) activities. A budget cap of $425,000 is set for the grant, with a strong preference for proposals that incorporate evidence-based approaches and demonstrate potential to address knowledge gaps among healthcare providers, thus improving treatment practices.

The FY24 PCRP Early Investigator Research Award supports prostate cancer-focused research opportunities for individuals in the early stages of their careers under the guidance of one or more designated mentors. This opportunity allows early-career investigators to develop a research project, investigate a problem or question in prostate cancer research, and further their intellectual development as prostate cancer researchers of the future. All application components for the FY24 PCRP Early Investigator Research Award are to be written by the Principal Investigator (PI), with appropriate direction from the mentor(s).Key elements of this award mechanism are as follows: Principal Investigator: The postdoctoral investigator is considered the PI of the application and must exhibit strong potential for and commitment to pursuing a career as an investigator at the forefront of prostate cancer research; however, the PI is not required to have previous prostate cancer research experience. The PI must have 3 years or less of postdoctoral research experience (excluding clinical residency or clinical fellowship training) as of March 31, 2025. The PCRP strongly encourages applications from PIs who demonstrate a commitment to pursuing a career focused on prostate cancer health disparity research. Mentor(s): Applications must include at least one mentor appropriate to the proposed research project who has experience in prostate cancer research and mentoring as demonstrated by a record of active funding, recent publications, and successful mentorship. The primary mentor can be a junior faculty member, in which case the PI is encouraged to include a secondary mentor with a more robust track record in prostate cancer research and mentorship. Applications that focus on prostate cancer health disparity should include at least one mentor with experience in prostate cancer health disparity research. The selected mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as a prostate cancer researcher. Research Approach: Proposed research ideas are required to address one or more of the FY24 PCRP Overarching Challenges. Projects that specifically address the FY24 PCRP Overarching Challenge to advance health equity and reduce disparities in prostate cancer are strongly encouraged. The scientific rationale and experimental methodology should demonstrate in-depth analysis of the research problem presented. The feasibility of the research design and methods should be well defined, and a clear plan should be articulated as to how the proposed goals of the project can be achieved. Inclusion of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required. Any preliminary data provided should be from the PI, mentor(s), or member(s) of the collaborating team. Additionally, required resources should be identified and supported through documentation. Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed under this funding opportunity. Researcher Development Plan: The PI must outline an individualized, prostate cancer-focused researcher development plan, which should include a clearly articulated strategy for acquiring the necessary skills, competence, and expertise that will enable the PI to successfully complete the proposed research project and foster the PIs development as an independent prostate cancer researcher. An environment appropriate to the proposed mentoring and research project must be clearly described, although any deficiencies of resources and/or mentorship at the PIs institution can be mitigated through collaboration(s) with other institutions. If the PI will be utilizing resources at another institution to successfully complete the proposed project, then the PI is strongly encouraged to designate a co-mentor at the collaborating institution.Investigators are strongly encouraged to incorporate the following components into their study design, where appropriate, in order to maximize the potential impact of the proposed research project: authentication of proposed cell lines; statistical rigor of preclinical animal experiments; and incorporation of experiments to assess clinical relevance and translatability of findings. Studies utilizing data derived from large patient studies that include long-term health records, biospecimen repositories, and pre-existing research and apply state-of-the-art genomic and/or proteomic analysis, bioinformatics, and/or mathematical models to such data are also encouraged. Investigators are highly encouraged to provide a letter of support indicating access to and the availability of any resources required to support the study.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (http://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP Early Investigator Research Award should not exceed $300,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $6.24M to fund approximately 13 Early Investigator Research Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The Water Resources Preservation Grant Program, funded by the Upper Guadalupe River Authority (UGRA), provides cost-share funding to support the design and construction of stormwater management practices. These practices, referred to as Best Management Practices (BMPs), include Low Impact Development (LID), nature-based solutions, and Green Stormwater Infrastructure (GSI). The goal is to reduce, infiltrate, filter, and delay stormwater runoff, thus protecting the health of waterways in Kerr County. Eligible projects can apply for rebates that cover a portion of the costs associated with these practices, with the aim of reducing pollutants like Total Suspended Solids (TSS) and Bacteria by significant percentages. The program supports new constructions or retrofits, emphasizes distributed and centralized treatment methods, and requires adherence to specific design guidelines.

This grant from Sanofi's Rare Blood Disorders Medical Affairs department focuses on medical education programs addressing Immune Thrombocytopenia (ITP). The grant aims to support independent medical education (IME) activities that recap highlights from EHA 2024 and ISTH 2024 conferences on ITP, emphasizing enduring programs, accredited or non-accredited IME activities, and digital or omnichannel formats. Proposals should address existing healthcare gaps in the treatment and management of ITP, improving clinician knowledge and patient outcomes. The maximum grant request is $150,000, with a focus on comprehensive interventions that address knowledge and performance gaps in ITP treatment. Proposals should cover target audience generation, learning objectives, educational methods, faculty recruitment, program evaluation, and budget planning.